Display options
Cite
Ruhaak LR, Barkauskas DA, Torres J, et al. The Serum Immunoglobulin G Glycosylation Signature of Gastric Cancer. EuPA Open Proteom. 2015;6:1-9doi: 10.1016/j.euprot.2014.11.002.
Ruhaak, L. R., Barkauskas, D. A., Torres, J., Cooke, C. L., Wu, L. D., Stroble, C., Ozcan, S., Williams, C. C., Camorlinga, M., Rocke, D. M., Lebrilla, C. B., & Solnick, J. V. (2015). The Serum Immunoglobulin G Glycosylation Signature of Gastric Cancer. EuPA open proteomics, 61-9. https://doi.org/10.1016/j.euprot.2014.11.002
Ruhaak, L Renee, et al. "The Serum Immunoglobulin G Glycosylation Signature of Gastric Cancer." EuPA open proteomics vol. 6 (2015): 1-9. doi: https://doi.org/10.1016/j.euprot.2014.11.002
Ruhaak LR, Barkauskas DA, Torres J, Cooke CL, Wu LD, Stroble C, Ozcan S, Williams CC, Camorlinga M, Rocke DM, Lebrilla CB, Solnick JV. The Serum Immunoglobulin G Glycosylation Signature of Gastric Cancer. EuPA Open Proteom. 2015 Mar 01;6:1-9. doi: 10.1016/j.euprot.2014.11.002. PMID: 25685702; PMCID: PMC4322429.
Copy Download .nbib Format: NLM
Share it on

EuPA Open Proteom. 2015 Mar 01;6:1-9. doi: 10.1016/j.euprot.2014.11.002.

The Serum Immunoglobulin G Glycosylation Signature of Gastric Cancer.

EuPA open proteomics

L Renee Ruhaak, Donald A Barkauskas, Javier Torres, Cara L Cooke, Lauren D Wu, Carol Stroble, Sureyya Ozcan, Cynthia C Williams, Margarita Camorlinga, David M Rocke, Carlito B Lebrilla, Jay V Solnick

Affiliations

  1. Department of Chemistry, University of California, Davis, CA, 95616.
  2. Department of Preventive Medicine, University of Southern California, Los Angeles, CA, 90089.
  3. Infectious Diseases Research Unit, Instituto Mexicano del Seguro Social, Mexico.
  4. Departments of Medicine and Microbiology & Immunology; Center for Comparative Medicine, University of California, Davis School of Medicine, Davis, CA, 95616.
  5. Department of Biomedical Engineering, University of California, Davis, CA, 95616 ; Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, CA, 95616.
  6. Department of Chemistry, University of California, Davis, CA, 95616 ; Department of Biochemistry and Molecular Medicine, University of California, Davis, CA 95616.

PMID: 25685702 PMCID: PMC4322429 DOI: 10.1016/j.euprot.2014.11.002

Abstract

Biomarkers may facilitate detection of gastric cancer at an earlier stage and reduce mortality. Here we sought to determine if the glycosylation profile of serum immunoglobulin G (IgG) could distinguish patients with non-atrophic gastritis (NAG), duodenal ulcer (DU) and gastric cancer (GC). Serum IgG was released and analyzed using nano-LC-TOF mass spectrometry. Statistically significant false discovery rate (FDR)-adjusted p-values were observed for 18 glycans, eight that differed significantly between NAG and GC, three that distinguished NAG from DU, and eight that differed between DU and GC. The IgG glycosylation signature may be useful as a predictive marker for gastric cancer.

Keywords: Gastric cancer; N-glycan; duodenal ulcer; gastritis; nanoLC-MS; serum

References

  1. Lancet Oncol. 2012 Jun;13(6):607-15 - PubMed
  2. Glycoconj J. 1997 Apr;14(3):401-5 - PubMed
  3. J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61 - PubMed
  4. Science. 2013 Jan 18;339(6117):286-91 - PubMed
  5. Lancet. 1988 Apr 30;1(8592):966-9 - PubMed
  6. J Proteome Res. 2009 Feb;8(2):694-701 - PubMed
  7. Glycoconj J. 1998 Jul;15(7):683-9 - PubMed
  8. J Proteome Res. 2013 Sep 6;12(9):4046-55 - PubMed
  9. Gastroenterology. 2007 Aug;133(2):659-72 - PubMed
  10. Proteomics. 2009 Jun;9(11):2986-94 - PubMed
  11. AIDS. 2005 Mar 4;19(4):381-9 - PubMed
  12. Glycobiology. 2010 Aug;20(8):959-69 - PubMed
  13. Glycoconj J. 2012 Jan;29(1):57-66 - PubMed
  14. Glycobiology. 2011 Feb;21(2):195-205 - PubMed
  15. Acta Pathol Microbiol Scand. 1965;64:31-49 - PubMed
  16. N Engl J Med. 1995 Jul 6;333(1):32-41 - PubMed
  17. Cancer. 1987 Sep 1;60(5):1099-106 - PubMed
  18. Crit Rev Oncol Hematol. 2005 Jun;54(3):209-41 - PubMed
  19. Am J Surg Pathol. 1996 Oct;20(10):1161-81 - PubMed
  20. J Proteome Res. 2013 Oct 4;12(10):4522-31 - PubMed
  21. Cancer Causes Control. 2013 Feb;24(2):209-15 - PubMed
  22. Cancer Prev Res (Phila). 2014 Feb;7(2):226-35 - PubMed
  23. J Proteome Res. 2011 Apr 1;10(4):1667-74 - PubMed
  24. J Proteome Res. 2010 Oct 1;9(10):4952-9 - PubMed
  25. J Proteome Res. 2012 Apr 6;11(4):2282-300 - PubMed
  26. Mol Cell Proteomics. 2013 Apr;12(4):846-55 - PubMed
  27. Analyst. 2011 Sep 21;136(18):3663-71 - PubMed
  28. Biochem J. 1989 Apr 15;259(2):347-53 - PubMed
  29. Nature. 1985 Aug 1-7;316(6027):452-7 - PubMed
  30. Proteomics. 2007 Nov;7(22):4070-81 - PubMed
  31. Arthritis Res Ther. 2009;11(6):R193 - PubMed
  32. Mol Cell Proteomics. 2012 Apr;11(4):M111.014563 - PubMed
  33. Anal Bioanal Chem. 2013 May;405(14):4953-8 - PubMed
  34. Nat Med. 2004 Apr;10(4):429-34 - PubMed
  35. Rejuvenation Res. 2007 Dec;10(4):521-531a - PubMed
  36. Proteomics. 2009 Apr;9(7):1939-51 - PubMed
  37. Mol Cell Proteomics. 2007 Jan;6(1):43-55 - PubMed
  38. Glycoconj J. 1998 Aug;15(8):737-47 - PubMed
  39. J Proteome Res. 2011 Jan 7;10(1):143-52 - PubMed
  40. J Infect Dis. 1998 Oct;178(4):1089-94 - PubMed
  41. Proteomics. 2008 Jan;8(1):8-20 - PubMed
  42. J Proteome Res. 2011 Apr 1;10(4):1755-64 - PubMed
  43. N Engl J Med. 1991 Oct 17;325(16):1127-31 - PubMed
  44. Ann Surg. 2005 Jan;241(1):27-39 - PubMed
  45. Proteomics. 2009 Feb;9(4):882-913 - PubMed
  46. Hum Antibodies Hybridomas. 1994;5(3-4):143-51 - PubMed
  47. Cancer Cell. 2005 Mar;7(3):211-7 - PubMed
  48. Anal Bioanal Chem. 2009 May;394(1):163-74 - PubMed
  49. PLoS One. 2010 Sep 07;5(9):e12566 - PubMed

Publication Types

Grant support